Faricimab

Experimental monoclonal antibody

Faricimab, sold under the brand name Vabysmo ( və-BYEZ-mow), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2).

Nº Q60785557 ★

Common · Knowledge

Faricimab

Experimental monoclonal antibody

Faricimab, sold under the brand name Vabysmo ( və-BYEZ-mow), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2).

Last price

—

Floor price

—

7-day median

—

30-day sales

0

30-day range

—

In circulation

0

Price history

Show table
Datemedian LowHighsales

Sales history

Last sale
—
30-day average
—
30-day low
—
30-day high
—
Sales 7d
0
Sales 30d
0

No sales yet.

Anonymous sales: no buyer or seller shown. Figures count player-to-player sales only.

From Wikipedia

Faricimab, sold under the brand name Vabysmo ( və-BYEZ-mow), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2). By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist. Faricimab was developed by Roche in Penzberg (Roche Innovation Center Munich). Faricimab was approved for medical use in the United States in January 2022, and in the European Union in September 2022.

Text: Wikipédia, CC BY-SA 4.0. · Image: Adjarock (CC BY-SA 4.0) ·

Related cards

View card

Confirmation